Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 7/20 | 0.35 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.35 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30488581 | 1.00 | AXL (0.42) | AXLMKNK1MKNK2TDP1PDPK1 | |
| SCHEMBL9837779 | 0.81 | ALDH1A1 (0.45) | AXLMKNK1MKNK2PDPK1PARP1 | |
| SCHEMBL3544906 | 0.81 | GPR35 (0.39) | AXLMKNK1MKNK2TDP1PDPK1 | |
| SCHEMBL17305955 | 0.81 | PDPK1 (0.40) | AXLMKNK1MKNK2TDP1PDPK1 | |
| SCHEMBL3543082 | 0.77 | POLB (0.37) | TDP1PDPK1PARP1MAPTALDH1A1 | |
| SCHEMBL30598786 | 0.77 | POLB (0.37) | TDP1PDPK1PARP1MAPTALDH1A1 | |
| SCHEMBL9836323 | 0.75 | TDP1 (0.38) | TDP1MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL31484406 | 0.74 | DYRK1A (0.39) | AXLMKNK1MKNK2TDP1MAPT | |
| SCHEMBL28471596 | 0.74 | PDE4A (0.40) | MAPTALDH1A1 | |
| SCHEMBL15655816 | 0.73 | GSK3B (0.48) | TDP1MAPTALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| US-20260055119-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| US-20250257071-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| EP-4582425-A1 | PRODRUG OF JAK KINASE INHIBITOR | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| US-20250129098-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2025-04-24 | — | — | US | disclosed |
| EP-4516321-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| US-20250002502-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2025-01-02 | — | — | US | disclosed |
| EP-4458830-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023207710-A9 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
| WO-2014071031-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20140121198-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-7683171-B2 | N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683171-B2 | N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683171-B2 | N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2007044050-A2 | 1H-IMIDAZO[4,5-D]THIENO[3,2-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20060178393-A1 | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
| EP-0223420-B1 | CONDENSED IMIDAZOPYRIDINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1991-02-27 | — | — | EP | disclosed |
| US-4753951-A | ANTIDEPRESSANTS, ANXIOLYTICS | SHIONOGI & CO., LTD. (JP) | 1988-06-28 | — | — | US | disclosed |
| EP-0223420-A1 | Condensed imidazopyridine derivatives | SHIONOGI & CO., LTD. (JP) | 1987-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | CD47, ABCB1, EGFR | AXL 728/4885MKNK1 4542/4885MKNK2 4311/4885 |
| US-20250257071-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | AXL 2011/4885MKNK1 4151/4885MKNK2 4194/4885 |
| US-20250129098-A1 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R1 | AXL 470/4885MKNK1 377/4885MKNK2 368/4885 |
| US-20260055119-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B1, CYP11B2, CYP2D6 | AXL 1753/4885MKNK1 4479/4885MKNK2 4496/4885 |
| US-20140121198-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | AXL 464/4885MKNK1 97/4885MKNK2 100/4885 |
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | AXL 103/4885MKNK1 1036/4885MKNK2 1404/4885 |
| US-20250002502-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | AXL 2011/4885MKNK1 4151/4885MKNK2 4194/4885 |
| US-20060178393-A1 | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | IL4, IL5, IRAK4 | AXL 3005/4885MKNK1 3265/4885MKNK2 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.